Serono Rebif Efficacy Gain Over Avonex Likely To Persist Past 48 Weeks–FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The efficacy advantage of Serono’s multiple sclerosis agent Rebif (interferon beta-1a) over Biogen’s Avonex (interferon beta-1a) will likely be maintained beyond 48 weeks, FDA reviewers concluded in review documents for the BLA.
You may also be interested in...
Pfizer/Serono Rebif superiority
Pfizer and Serono add 48-week data from the EVIDENCE study to Rebif labeling, firms announce May 22. The head-to-head study showed that multiple sclerosis patients treated with subcutaneous Rebif 44 mcg three times weekly "were more likely to remain relapse-free at 24 and 48 weeks" than patients treated with Biogen's Avonex 30 mcg intramuscular once weekly. At 48 weeks, 62% of Rebif (interferon beta-1a) patients remained relapse-free versus 52% of Avonex (interferon beta-1a) patients. Rebif was approved March 7, 2002, despite Avonex' orphan exclusivity, based on an advantage in 24-week relapse data. FDA reviewers predicted Rebif's superiority would likely be maintained beyond 48 weeks (1Pharmaceutical Approvals Monthly April 1, 2002, p. 4). Biogen has a long-term comparative trial underway. The approval also covers storage of Rebif at room temperature "for up to 30 days"...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product